|
US7646707B2
(en)
*
|
2003-12-23 |
2010-01-12 |
At&T Intellectual Property I, L.P. |
Method and system for automatically renaming logical circuit identifiers for rerouted logical circuits in a data network
|
|
CA2553871A1
(en)
*
|
2004-01-16 |
2005-08-04 |
The Regents Of The University Of Michigan |
Smac peptidomimetics and the uses thereof
|
|
US7932382B2
(en)
*
|
2004-01-16 |
2011-04-26 |
The Regents Of The University Of Michigan |
Conformationally constrained Smac mimetics and the uses thereof
|
|
RS52545B
(sr)
|
2004-04-07 |
2013-04-30 |
Novartis Ag |
Inhibitori protein apoptoze (iap)
|
|
BRPI0511350A
(pt)
*
|
2004-07-02 |
2007-12-04 |
Genentech Inc |
composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto
|
|
US7674787B2
(en)
*
|
2004-07-09 |
2010-03-09 |
The Regents Of The University Of Michigan |
Conformationally constrained Smac mimetics and the uses thereof
|
|
EP1773348A4
(en)
*
|
2004-07-12 |
2009-05-20 |
Idun Pharmaceuticals Inc |
TETRA PEPTIDE ANALOGS
|
|
AU2005274937B2
(en)
*
|
2004-07-15 |
2011-08-18 |
Medivir Ab |
IAP binding compounds
|
|
MX2007007195A
(es)
|
2004-12-20 |
2007-10-08 |
Genentech Inc |
Inhibidores de pirrolidina de iap.
|
|
ES2456671T3
(es)
|
2005-02-25 |
2014-04-23 |
Tetralogic Pharmaceuticals Corporation |
Inhibidores diméricos de IAP
|
|
US7772177B2
(en)
|
2005-05-18 |
2010-08-10 |
Aegera Therapeutics, Inc. |
BIR domain binding compounds
|
|
WO2007021825A2
(en)
*
|
2005-08-09 |
2007-02-22 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
|
US20100256046A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
|
WO2007048224A1
(en)
|
2005-10-25 |
2007-05-03 |
Aegera Therapeutics Inc. |
Iap bir domain binding compounds
|
|
WO2007106192A2
(en)
|
2005-12-19 |
2007-09-20 |
Genentech, Inc. |
Inhibitors of iap
|
|
TWI504597B
(zh)
|
2006-03-16 |
2015-10-21 |
Pharmascience Inc |
結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
|
|
AU2007250443B2
(en)
|
2006-05-16 |
2013-06-13 |
Pharmascience Inc. |
IAP BIR domain binding compounds
|
|
WO2008014238A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
US20100056495A1
(en)
*
|
2006-07-24 |
2010-03-04 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
WO2008014240A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
KR20090041391A
(ko)
|
2006-07-24 |
2009-04-28 |
테트랄로직 파마슈티칼스 |
이량체성 ｉａｐ 길항제
|
|
WO2008014229A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
CL2007002166A1
(es)
|
2006-07-24 |
2008-01-25 |
Tetralogic Pharm Corp |
Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
|
|
PE20110220A1
(es)
|
2006-08-02 |
2011-04-11 |
Novartis Ag |
DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
|
|
JP2010501567A
(ja)
*
|
2006-08-24 |
2010-01-21 |
ノバルティス アクチエンゲゼルシャフト |
代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物
|
|
KR20090053923A
(ko)
*
|
2006-09-22 |
2009-05-28 |
노파르티스 아게 |
헤테로시클릭 유기 화합물
|
|
US8044209B2
(en)
|
2006-10-12 |
2011-10-25 |
Novartis Ag |
Pyrrolydine derivatives as IAP inhibitors
|
|
US8063218B2
(en)
*
|
2006-12-19 |
2011-11-22 |
Genentech, Inc. |
Imidazopyridine inhibitors of IAP
|
|
CN101595105B
(zh)
*
|
2006-12-20 |
2013-01-23 |
诺瓦提斯公司 |
作为scd抑制剂的2-取代的5元杂环化合物
|
|
JP5454943B2
(ja)
*
|
2007-04-12 |
2014-03-26 |
ジョイアント ファーマスーティカルズ、インク． |
抗癌剤として有用なｓｍａｃ模倣二量体及び三量体
|
|
PE20130150A1
(es)
*
|
2007-04-30 |
2013-02-27 |
Genentech Inc |
Inhibidores de las iap
|
|
JP2010528587A
(ja)
*
|
2007-05-07 |
2010-08-26 |
テトラロジック ファーマシューティカルズ コーポレーション |
アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法
|
|
WO2008144925A1
(en)
*
|
2007-05-30 |
2008-12-04 |
Aegera Therapeutics Inc. |
Iap bir domain binding compounds
|
|
ES2398791T3
(es)
*
|
2008-01-11 |
2013-03-21 |
Genentech, Inc. |
Inhibidores de IAP
|
|
WO2009136290A1
(en)
*
|
2008-05-05 |
2009-11-12 |
Aegera Therapeutics, Inc. |
Functionalized pyrrolidines and use thereof as iap inhibitors
|
|
WO2009155709A1
(en)
*
|
2008-06-27 |
2009-12-30 |
Aegera Therapeutics Inc. |
Bridged secondary amines and use thereof as iap bir domain binding compounds
|
|
CN102171209A
(zh)
*
|
2008-08-02 |
2011-08-31 |
健泰科生物技术公司 |
Iap抑制剂
|
|
JP2012500272A
(ja)
*
|
2008-08-16 |
2012-01-05 |
ジェネンテック， インコーポレイテッド |
Ｉａｐのアザインドールインヒビター
|
|
AU2009293403A1
(en)
|
2008-09-17 |
2010-03-25 |
Tetralogic Pharmaceuticals Corp. |
IAP inhibitors
|
|
FR2939073B1
(fr)
|
2008-12-03 |
2010-12-31 |
Sidel Participations |
Formage des recipients avec contre-pression localisee
|
|
US20100317593A1
(en)
*
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
|
US8283372B2
(en)
|
2009-07-02 |
2012-10-09 |
Tetralogic Pharmaceuticals Corp. |
2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
|
|
WO2011035083A1
(en)
|
2009-09-18 |
2011-03-24 |
Novartis Ag |
Biomarkers for iap inhibitor compounds
|
|
EP2784076A1
(en)
|
2009-10-28 |
2014-10-01 |
Joyant Pharmaceuticals, Inc. |
Dimeric SMAC mimetics
|
|
CN102050867A
(zh)
*
|
2009-11-10 |
2011-05-11 |
上海艾力斯医药科技有限公司 |
四肽类似物、制备方法及其应用
|
|
WO2011098904A1
(en)
|
2010-02-12 |
2011-08-18 |
Aegera Therapeutics, Inc. |
Iap bir domain binding compounds
|
|
EP2558458B1
(de)
|
2010-04-16 |
2017-09-06 |
Bayer Intellectual Property GmbH |
Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
|
|
GB201106817D0
(en)
|
2011-04-21 |
2011-06-01 |
Astex Therapeutics Ltd |
New compound
|
|
WO2013043591A1
(en)
*
|
2011-09-21 |
2013-03-28 |
Albert Einstein College Of Medicine Of Yeshiva University |
Combination therapy for cancer
|
|
CA2850330A1
(en)
|
2011-09-30 |
2013-04-04 |
Tetralogic Pharmaceuticals Corporation |
Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
|
|
NO2755614T3
(https=)
*
|
2012-01-03 |
2018-03-31 |
|
|
|
US9353419B2
(en)
|
2012-05-04 |
2016-05-31 |
Novartis Ag |
Biomarkers for IAP inhibitor therapy
|
|
US9546174B2
(en)
|
2012-11-30 |
2017-01-17 |
Sanford-Burnham Medical Research Institute |
Inhibitor of apoptosis protein (IAP) antagonists
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
NZ710929A
(en)
|
2013-03-15 |
2018-02-23 |
Novartis Ag |
Antibody drug conjugates
|
|
CN105451726B
(zh)
|
2013-06-25 |
2021-03-16 |
沃尔特和伊利莎豪医学研究所 |
治疗细胞内感染的方法
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
ES2883289T3
(es)
|
2013-12-20 |
2021-12-07 |
Astex Therapeutics Ltd |
Compuestos heterocíclicos bicíclicos y sus usos en terapia
|
|
WO2015109391A1
(en)
|
2014-01-24 |
2015-07-30 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Smc combination therapy for the treatment of cancer
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
WO2015168835A1
(en)
*
|
2014-05-05 |
2015-11-12 |
Empire Technology Development Llc |
Composite task processor
|
|
WO2015187998A2
(en)
|
2014-06-04 |
2015-12-10 |
Sanford-Burnham Medical Research Institute |
Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
|
|
US10786578B2
(en)
|
2014-08-05 |
2020-09-29 |
Novartis Ag |
CKIT antibody drug conjugates
|
|
KR20170040249A
(ko)
|
2014-08-12 |
2017-04-12 |
노파르티스 아게 |
항-cdh6 항체 약물 접합체
|
|
GB201414730D0
(en)
|
2014-08-19 |
2014-10-01 |
Tpp Global Dev Ltd |
Pharmaceutical compound
|
|
WO2016079527A1
(en)
|
2014-11-19 |
2016-05-26 |
Tetralogic Birinapant Uk Ltd |
Combination therapy
|
|
WO2016097773A1
(en)
|
2014-12-19 |
2016-06-23 |
Children's Cancer Institute |
Therapeutic iap antagonists for treating proliferative disorders
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
EP3310813A1
(en)
|
2015-06-17 |
2018-04-25 |
Novartis AG |
Antibody drug conjugates
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
TN2018000112A1
(en)
|
2015-10-29 |
2019-10-04 |
Novartis Ag |
Antibody conjugates comprising toll-like receptor agonist
|
|
HUE064412T2
(hu)
|
2016-06-21 |
2024-03-28 |
Orion Ophthalmology LLC |
Heterociklusos prolinamid-származékok
|
|
JP7164521B2
(ja)
|
2016-06-21 |
2022-11-01 |
オリオン・オフサルモロジー・エルエルシー |
炭素環式プロリンアミド誘導体
|
|
IL290809B2
(en)
|
2016-11-01 |
2024-01-01 |
Arvinas Operations Inc |
Tau-protein targeting protacs and associated methods of use
|
|
KR102674902B1
(ko)
|
2016-12-01 |
2024-06-14 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
|
|
MX2019007646A
(es)
|
2016-12-23 |
2019-09-06 |
Arvinas Operations Inc |
Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso.
|
|
CN117510491A
(zh)
|
2016-12-23 |
2024-02-06 |
阿尔维纳斯运营股份有限公司 |
用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
AU2018211975B2
(en)
|
2017-01-26 |
2022-05-26 |
Arvinas Operations, Inc. |
Modulators of estrogen receptor proteolysis and associated methods of use
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
WO2018163051A1
(en)
|
2017-03-06 |
2018-09-13 |
Novartis Ag |
Methods of treatment of cancer with reduced ubb expression
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
EP3630162A1
(en)
|
2017-05-24 |
2020-04-08 |
Novartis AG |
Antibody-cytokine engrafted proteins and methods of use
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
BR112019024556A2
(pt)
|
2017-05-24 |
2020-06-23 |
Novartis Ag |
Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
|
|
KR102707188B1
(ko)
*
|
2017-11-13 |
2024-09-13 |
치아타이 티안큉 파마수티컬 그룹 주식회사 |
Iap 억제제로서 유용한 smac 모방물 및 그 용도
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
JP7161849B2
(ja)
*
|
2018-01-24 |
2022-10-27 |
株式会社クラレ |
第一級アミンの製造方法
|
|
WO2019154053A1
(zh)
*
|
2018-02-09 |
2019-08-15 |
广东东阳光药业有限公司 |
Iap抑制剂及其在药物中的应用
|
|
KR20210006356A
(ko)
|
2018-04-04 |
2021-01-18 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해 조절제 및 연관된 사용 방법
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
DK3820573T3
(da)
|
2018-07-10 |
2023-10-23 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme
|
|
US20200038513A1
(en)
|
2018-07-26 |
2020-02-06 |
Arvinas Operations, Inc. |
Modulators of fak proteolysis and associated methods of use
|
|
EP3841100A1
(en)
|
2018-08-20 |
2021-06-30 |
Arvinas Operations, Inc. |
Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
|
|
KR102642203B1
(ko)
|
2018-09-07 |
2024-03-04 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법
|
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
JP7607564B2
(ja)
|
2018-12-21 |
2024-12-27 |
ノバルティス アーゲー |
Ｐｍｅｌ１７に対する抗体及びその結合体
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN113490528B
(zh)
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
EP3936126A4
(en)
*
|
2019-03-07 |
2022-12-21 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
COMBINATION OF IAP INHIBITOR AND IMMUNOCHECK POINT INHIBITOR
|
|
MX2021013729A
(es)
*
|
2019-05-10 |
2021-12-10 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
Cristalina de imitador smac utilizado como inhibidor de iap y metodo de preparacion del mismo.
|
|
CN119954801A
(zh)
|
2019-07-17 |
2025-05-09 |
阿尔维纳斯运营股份有限公司 |
Tau蛋白靶向化合物及相关使用方法
|
|
WO2021023698A1
(en)
|
2019-08-02 |
2021-02-11 |
Lanthiopep B.V |
Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
|
|
IL320609A
(en)
|
2019-08-26 |
2025-07-01 |
Arvinas Operations Inc |
Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
|
|
MX2022007759A
(es)
|
2019-12-20 |
2022-07-19 |
Novartis Ag |
Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
|
|
JP2023510426A
(ja)
|
2020-01-20 |
2023-03-13 |
アストラゼネカ・アクチエボラーグ |
癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
|
|
CN111205232B
(zh)
*
|
2020-02-26 |
2022-07-01 |
浙江天宇药业股份有限公司 |
一种替格瑞洛中间体的合成方法
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
CA3185455A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
JP7834721B2
(ja)
|
2020-08-28 |
2026-03-24 |
アルビナス・オペレーションズ・インコーポレイテッド |
急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
|
|
AR123492A1
(es)
|
2020-09-14 |
2022-12-07 |
Arvinas Operations Inc |
Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
CA3235132A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
CN119301125A
(zh)
|
2022-07-26 |
2025-01-10 |
诺华股份有限公司 |
Akr1c3依赖性kars抑制剂的晶型
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
CN121419983A
(zh)
|
2023-01-26 |
2026-01-27 |
阿尔维纳斯运营股份有限公司 |
基于小脑蛋白的kras降解protac及其相关用途
|